Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415).

Furthermore, patients in group A showed a trend to lower PD-L1 TPS values ( p = 0.042–0.452 for various cut-off values, Table 1 ), which was also associated with poorer response to ICI therapy in the current (Supplementary Table 1) and previous studies [ 30 ].

also in 25,348 other papers